All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-01-30T11:05:09.000Z

FDA issues new boxed warning for CAR T-cell therapies

Jan 30, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in CAR T-cell therapy.

Bookmark this article

On January 19, 2024, the Food and Drug Administration (FDA) authorized a mandate black box warning be included on all chimeric antigen receptor (CAR) T-cell therapies prescribing information, in letters sent to CAR-T therapy manufacturers.

Initially, the benefits of CAR T-cell therapy in lymphoma, leukemia, and multiple myeloma were thought to outweigh the risk of T-cell malignancy. However, in November 2023 the FDA emphasized a need to monitor CAR T-cell therapy clinical trials and post-marketing adverse event reporting throughout patients’ entire lives, enabling the identification of new malignancies and testing for the CAR gene when they occur.

Currently, six CAR T-cell therapies have been approved in the US :

  • tisagenlecleucel
  • brexucabtagene autoleucel
  • ciltacabtagene autoleucel
  • lisocabtagene maraleucel
  • idecabtagene vicleucel
  • axicabtagene ciloleucel

This warning is based on 20 cases of T-cell malignancy reported in 34,000 patients who received approved CAR T-cell therapies. Since then, The International Society for Cell & Gene Therapy published a consensus statement supporting the view CAR T-cell therapies’ benefits to patients outweigh the risks in most cases. However, more information, such as patient characteristics, genetic mutations, and timing of development should be collected to fully elucidate the risk associated with CAR T-cell therapy and T-cell malignancies.

  1. Managed Healthcare Exec. FDA requires new boxed warning for CAR-T therapies. https://www.managedhealthcareexecutive.com/view/fda-requires-new-boxed-warning-for-car-t-therapies. Published Jan 25, 2024. Accessed Jan 29, 2024.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox